Clinic Outcome of HD-MTX-Ara-C Regimen Treating Patients With Refractory and Relapse Acute Myeloid Leukemia

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000032106

Enrollment

Unknown

Registered

2020-04-20

Start date

2020-05-01

Completion date

Unknown

Last updated

2020-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory and Relapse Acute Myeloid Leukemia

Interventions

experimental group:HYPER-B program

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients aged 18 to 65 years with Refractory and Relapse Acute Myeloid Leukemia were eligible. 2. Have no renal or hepatic dysfunction (serum creatinine level ? 3 upper limit of normal (ULN), bilirubin level ? 2 ULN, AST level ? 2.5 ULN, or ALT level ? 2.5 ULN). 3. ECOG performance status of 2 or less. 4. Written informed consent was obtained from all patients.

Exclusion criteria

Exclusion criteria: 1. Have specificity taget gene mutation but have no tageted therapy; 2. Subject is pregnant. uncontrolled activity infection; 3. Suffered mental illness; 4. Uncontrolled other desease; 5. Any other co-morbidity that, in the opinion of the investigator, predisposes the subject to high risk of noncompliance with the protocol.

Design outcomes

Primary

Measure	Time frame
complete remission;treatment-related death;Treatment related safety indicators (mainly including bacterial infection, viral infection and fungal infection);	—

Secondary

Measure	Time frame
OS;DFS;	—

Countries

China

Contacts

Public ContactWang Jing

Peking University, People's Hospital, Peking University Institute of Hematology

wangjing5982@126.com+86 010-82816666-8035

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026